Sign up
An elderly couple cooks together and talks in the kitchen

Possibly new drug that slows down Alzheimer's disease

28 September 2022 2 minute reading time

Pharmaceutical companies Eisai and Biogen announced on Wednesday, September 28, that they have developed a drug that slows the progression of Alzheimer's disease.

The drug Lecanemab reduces the deterioration of cognitive functions (such as memory and problem solving) over a period of 18 months by 27 percent compared to a group that received placebo.

The drug has not yet been approved. That is the next step that must now be taken. Both by the American and the European Medicines Agency. The results of the study will be presented on November 29 at an international congress.

Niels Prins, director of the Brain Research Center, which specializes in testing drugs against brain diseases such as Alzheimer’s, is delighted by the news. ’This could be a breakthrough. The results look better this time than in previous studies. The drug does not cure the disease, but it does slow down the progression. And that last point is relevant. Using this drug could mean that over five years you have one year less decline. Furthermore, we see that Lecanemab has a positive effect on the amount of amyloid plaques, a buildup of certain proteins that contribute to Alzheimer’s. It removes these proteins.’

For the researchers, the result is a milestone. For many years, pharmacists have been searching for a drug that can slow down or eventually cure Alzheimer's disease. So far without success. Last year, the drug Aducanumab seemed to be the solution, but it was ultimately not approved for the European market.

The new drug Lecanemab is also still facing a long road ahead. But according to Niels Prins, the prospects seem much better. On average, it takes one and a half years before a drug is approved for the Dutch market. Then it will also become clear at what price and under what conditions the drug will be available.